Document is current

Article History

Received: 19 January 2023

Accepted: 28 January 2024

First Online: 4 February 2024

Competing interests

: S. C. M. filed a patent application on selected aspects of the prime-and-trap concept through the University of Washington. S. C. M. has equity in a startup company (Sound Vaccines, Inc.) that is negotiating with the University of Washington for rights to this intellectual property. The relationship between the authors and Sound Vaccines, Inc., has been reviewed by the University of Washington and complies with all University and State of Washington policies on such activities. S. C., B. K. L. S., and S. L. H. are paid employees of Sanaria Inc. M. T., S. C., and S. L. H. are inventors on two patents related to 7DW8-5 and <i>Plasmodium</i> SPZ, both of which are assigned in part to Sanaria Inc.—(1) Title: Pharmaceutical Compositions Comprising Attenuated Sporozoites and Glycolipid Adjuvants. Inventors: Chakravarty, Hoffman, and Tsuji. Date of Filing: October 28, 2013, Date of Issue: March 8, 2016. US Patent Issue Number: 9,278,125. (2) Title: Pharmaceutical Compositions Comprising Attenuated Sporozoites and Glycolipid Adjuvants (methods of use). Inventors: Chakravarty, Hoffman, and Tsuji. Date of Filing: February 18, 2016, Date of Issue: May 9, 2017. US Patent Issue Number: 9,642,909. M. T. is also an inventor of four patents related to 7DW8-5, all of which are assigned to Rockefeller University. (1) Glycolipids and analogues thereof as antigens for NK T cells. Date of Issue: May 19, 2009. US Patent Issue Number: 7,534,434. (2) Glycolipids and analogues thereof as antigens for NK T cells. Date of Issue: April 12, 2011. US Patent Issue Number: 7,923,013. (3) Glycolipids and analogues thereof as antigens for NK T cells. Date of Issue: April 24, 2012. US Patent Issue Number: 8,163,290 B2. (4) Glycolipids and analogues thereof as antigens for NK T cells. Date of Issue: November 19, 2013.US Patent Issue Number: 8,586,051. The other authors have no financial conflicts of interest.